HLB Pharmaceutical Co., Ltd (047920.KQ)
KRW 25850.0
(-6.34%)
KRW 25850.0
(-6.34%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 102.52 Billion KRW | 44.23% |
| 2022 | 70.59 Billion KRW | 103.52% |
| 2021 | 34.68 Billion KRW | 63.52% |
| 2020 | 21.21 Billion KRW | 28.87% |
| 2019 | 16.46 Billion KRW | 59.17% |
| 2018 | 10.34 Billion KRW | 52.5% |
| 2017 | 6.78 Billion KRW | 46.59% |
| 2016 | 4.62 Billion KRW | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 20.21 Billion KRW | -14.82% |
| 2024 Q2 | 21.2 Billion KRW | 4.91% |
| 2023 Q3 | 27.94 Billion KRW | -10.04% |
| 2023 FY | 101.82 Billion KRW | 44.23% |
| 2023 Q4 | 23.72 Billion KRW | -15.11% |
| 2023 Q2 | 31.07 Billion KRW | 65.39% |
| 2023 Q1 | 18.78 Billion KRW | -35.15% |
| 2022 FY | 70.59 Billion KRW | 103.52% |
| 2022 Q1 | 12.46 Billion KRW | 27.88% |
| 2022 Q4 | 28.96 Billion KRW | 72.88% |
| 2022 Q3 | 16.75 Billion KRW | 38.68% |
| 2022 Q2 | 12.08 Billion KRW | -3.08% |
| 2021 Q3 | 9.11 Billion KRW | 0.0% |
| 2021 FY | 34.68 Billion KRW | 63.52% |
| 2021 Q4 | 9.74 Billion KRW | 6.89% |
| 2020 FY | 21.21 Billion KRW | 28.87% |
| 2019 FY | 16.46 Billion KRW | 59.17% |
| 2018 FY | 10.34 Billion KRW | 52.5% |
| 2017 FY | 6.78 Billion KRW | 46.59% |
| 2016 FY | 4.62 Billion KRW | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| CMG Pharmaceutical Co., Ltd. | 37.86 Billion KRW | -170.76% |
| Celltrion Pharm, Inc. | 80.93 Billion KRW | -26.676% |
| Huons Global Co., Ltd. | 294.87 Billion KRW | 65.231% |
| DongKook Pharmaceutical Co., Ltd. | 338.16 Billion KRW | 69.682% |
| Enzychem Lifesciences Corporation | 18.7 Billion KRW | -448.15% |
| Humedix Co., Ltd. | 33.04 Billion KRW | -210.28% |
| Boditech Med Inc. | 47.05 Billion KRW | -117.902% |
| EuBiologics Co., Ltd. | 24.95 Billion KRW | -310.767% |
| FutureChem Co.,Ltd | 9.16 Billion KRW | -1018.542% |
| Huons Co., Ltd. | 226.14 Billion KRW | 54.663% |
| BNC Korea Co., Ltd. | 25.19 Billion KRW | -306.872% |
| AptaBio Therapeutics Inc. | 16.45 Billion KRW | -523.191% |